NZ554723A - Antisense oligonucleotides against CCR3 chemokine receptor - Google Patents

Antisense oligonucleotides against CCR3 chemokine receptor

Info

Publication number
NZ554723A
NZ554723A NZ554723A NZ55472305A NZ554723A NZ 554723 A NZ554723 A NZ 554723A NZ 554723 A NZ554723 A NZ 554723A NZ 55472305 A NZ55472305 A NZ 55472305A NZ 554723 A NZ554723 A NZ 554723A
Authority
NZ
New Zealand
Prior art keywords
oligonucleotide
seq
pharmaceutical composition
antisense oligonucleotide
antisense
Prior art date
Application number
NZ554723A
Other languages
English (en)
Inventor
Khalid Zemzoumi
Paolo Renzi
Original Assignee
Topigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topigen Pharmaceuticals Inc filed Critical Topigen Pharmaceuticals Inc
Publication of NZ554723A publication Critical patent/NZ554723A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ554723A 2004-10-29 2005-10-27 Antisense oligonucleotides against CCR3 chemokine receptor NZ554723A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62320604P 2004-10-29 2004-10-29
PCT/CA2005/001656 WO2006045202A1 (en) 2004-10-29 2005-10-27 Antisense oligonucleotides for treating allergy and neoplastic cell proliferation

Publications (1)

Publication Number Publication Date
NZ554723A true NZ554723A (en) 2009-12-24

Family

ID=36226992

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ554723A NZ554723A (en) 2004-10-29 2005-10-27 Antisense oligonucleotides against CCR3 chemokine receptor

Country Status (12)

Country Link
US (2) US8119790B2 (enExample)
EP (1) EP1812075B1 (enExample)
JP (1) JP5314283B2 (enExample)
CN (1) CN101087623B (enExample)
AU (1) AU2005299218B2 (enExample)
BR (1) BRPI0517387A8 (enExample)
CA (1) CA2584457C (enExample)
ES (1) ES2450929T3 (enExample)
MX (1) MX2007005083A (enExample)
NZ (1) NZ554723A (enExample)
RU (1) RU2416412C2 (enExample)
WO (1) WO2006045202A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285961A4 (en) 2008-05-15 2012-10-17 Topigen Pharmaceuticals Inc OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION
MX343559B (es) 2010-04-29 2016-11-10 Ionis Pharmaceuticals Inc Modulacion de la expresion de transtiretina.
SG192869A1 (en) * 2011-02-24 2013-09-30 Pharmaxis Ltd Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine
WO2013026059A1 (en) * 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
CA3002761A1 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) * 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) * 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5646265A (en) * 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US5874211A (en) 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils
FR2734147B1 (fr) 1995-05-19 1997-10-10 Klein Jean Michel Dispositif d'osteosynthese implantable
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US6229006B1 (en) 1995-12-22 2001-05-08 Smithkline Beecham Corporation Use of antisense oligodeoxynucleotides to produce truncated proteins
AUPN780096A0 (en) 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
CA2252432A1 (en) 1996-04-26 1997-11-06 Incyte Pharmaceuticals, Inc. Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
CA2252850A1 (en) 1996-04-26 1997-11-06 Merck & Co., Inc. Eosinophil eotaxin receptor
US5807708A (en) * 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
IL135140A0 (en) 1997-09-17 2001-05-20 Univ East Carolina Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
EP1088066B1 (en) 1998-06-19 2006-11-29 McGILL UNIVERSITY Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
CA2333901A1 (en) 1998-08-03 2000-02-24 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
US6175004B1 (en) 1998-09-01 2001-01-16 Isis Pharmaceuticals, Inc. Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
IL140054A0 (en) 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
ATE293688T1 (de) 2000-09-06 2005-05-15 Univ Mcgill Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
DK1406667T3 (da) * 2001-07-06 2008-06-16 Topigen Pharmaceuticals Inc Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr
ATE348104T1 (de) 2001-10-29 2007-01-15 Univ Mcgill Azyklische linker enthaltende oligonukleotide und deren verwendungen
MXPA04007403A (es) 2002-02-01 2005-07-01 Univ Mcgill Oligonucleotidos que comprenden segmentos alternos y usos de los mismos.

Also Published As

Publication number Publication date
MX2007005083A (es) 2007-10-03
RU2007119777A (ru) 2008-12-10
EP1812075B1 (en) 2013-12-11
US20120065249A1 (en) 2012-03-15
EP1812075A4 (en) 2010-04-07
CA2584457C (en) 2012-10-23
AU2005299218A1 (en) 2006-05-04
US8202851B2 (en) 2012-06-19
US20090215861A1 (en) 2009-08-27
CN101087623A (zh) 2007-12-12
EP1812075A1 (en) 2007-08-01
JP2008517953A (ja) 2008-05-29
BRPI0517387A8 (pt) 2017-07-11
CA2584457A1 (en) 2006-05-04
JP5314283B2 (ja) 2013-10-16
US8119790B2 (en) 2012-02-21
AU2005299218A2 (en) 2008-10-30
RU2416412C2 (ru) 2011-04-20
ES2450929T3 (es) 2014-03-25
CN101087623B (zh) 2012-09-26
WO2006045202A1 (en) 2006-05-04
BRPI0517387A (pt) 2008-10-07
AU2005299218B2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
US8470999B2 (en) Oligonucleotides for treating inflammation and neoplastic cell proliferation
AU2004275903B2 (en) Oligonucleotide compositions and methods for treating disease including inflammatory conditions
US20150225722A1 (en) Methods for selective targeting of heterochromatin forming non-coding rna
US8202851B2 (en) Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
WO2019040590A1 (en) MODULATION OF THE EXPRESSION OF SOLUBLE FAS
JP2022513111A (ja) Ａｎｇｐｔｌ８を阻害するための新規のｒｎａ組成物および方法
AU2007252192B2 (en) Oligonucleotides affecting expression of phosphodiesterases
JP7241098B2 (ja) 線維症治療剤
CA2827782A1 (en) Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine

Legal Events

Date Code Title Description
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: THE APPLICANT (71) HAS BEEN CORRECTED

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2016 BY WRAYS

Effective date: 20150812

ASS Change of ownership

Owner name: PHARMAXIS LTD, AU

Effective date: 20160602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2017 BY WRAYS

Effective date: 20160928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2018 BY WRAYS

Effective date: 20171002

LAPS Patent lapsed